摘要
目的探讨肝癌患者血清趋化因子12和IL-6水平与其复发转移的关系。方法采用ELISA法,测定40例肝癌患者(肝癌组)和30例健康者(健康组)血清趋化因子12和IL-6水平,并分析其与复发转移的关系。结果治疗前后肝癌组的血清趋化因子12和IL-6水平均高于健康组;肝癌组治疗后的血清趋化因子12和IL-6水平低于治疗前(P<0.05);出现复发和转移肝癌患者血清趋化因子12和IL-6水平明显高于无复发或转移患者(P<0.05)。肝癌患者血清趋化因子12和IL-6水平与其转移率和复发率均呈正相关。结论肝癌患者血清趋化因子12和IL-6水平增高且与其复发转移相关,可能作为其复发转移等预后情况评估的参考指标。
Objective To study the relationship between the serum CXCL 12 and IL-6 level in liver cancer patients with recurrence and metastasis.Methods ELISA methods was applied to test the serum CXCL 12 and IL-6 level in 40 liver cancer pa-tients（liver cancer group）and 30 health people（health group）,and analyzed their relationship with recurrence and metastasis.Results Before and after the treatment the serum CXCL 12 and IL-6 level in liver cancer patients were both higher than that of the normal group;the serum CXCL12 and IL-6 level in liver cancer patients was lower than after treatment （P〈0.05）;the serum CXCL12 and IL-6 level in patients with recurrence and metastasis were higher than that of patients without recurrence or metasta -sis（P〈0.05）.The serum CXCL12 and IL-6 level in liver cancer patients were positively related with the liver cancer recurrence rate and metastasis rate（CXCL12：γ=0.687,0.693;IL-6：γ=0.722,0.718 ,P〈0.05）.Conclusion The serum CXCL12 and IL-6 level in liver cancer patients are related with recurrence and metastasis of liver cancer.They may be predictive indicators for recurrence ,metastasis and prognosis.
出处
《实用癌症杂志》
2017年第1期27-29,共3页
The Practical Journal of Cancer
